Mezlocillin for treatment of infections in cancer patients.
Mezlocillin, at a dose of 3 g intravenously over a 2-h period every 4 h, was used for the treatment of 92 episodes of documented infections in 75 myelosuppressed cancer patients. The response rate in 59 evaluable bacterial infections was 46%. Eight of 23 patients with septicemia (35%) responded. The...
Gorde:
| Argitaratua izan da: | Antimicrob Agents Chemother |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society for Microbiology (ASM)
1980
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC283920/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6447474/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.17.6.1008 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|